1774-1775 / 2437
• Heterogeneous cohorts with respect to standard treatment
and timing of valganciclovir
• Valganciclovir was given only “
when there was no
evidence of progression
”
Selection of patients with valganciclovir exposure of 6
months after surgery or after 6 months of standard
treatment
Enrichment for favorable outcome
Creation of a new long-term benefitting sub-group of
patients
• No documentation of factors associated with longer
survival, e.g. extent of resection, IDH, MGMT etc.
Valganciclovir-treated patients
vs.
contemporary controls